PCM
ARRY

Piermont Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Piermont Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-18,660
Closed -$313K – 252
2018
Q2 		$313K Sell
18,660
-3,430
-16% -$54.6K 0.1% 207
2018
Q1 		$361K Sell
22,090
-3,470
-14% -$55.6K 0.12% 206
2017
Q4 		$327K Sell
25,560
-1,430
-5% -$16.3K 0.11% 215
2017
Q3 		$332K Sell
26,990
-26,310
-49% -$244K 0.11% 217
2017
Q2 		$446K Sell
53,300
-9,600
-15% -$78.5K 0.13% 231
2017
Q1 		$562K Buy
+62,900
New +$669K 0.13% 225

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Piermont Capital Management's ARRY Position: Q3 2018 in Review

Piermont Capital Management sold out of Array Biopharma Inc (ARRY) in Q3 2018, closing a stake of 18,660 shares — an estimated $313K sold.

Piermont Capital Management first reported a position in ARRY in Q1 2017 and held it in 6 quarters. The position peaked at $562K in Q1 2017. 208 funds tracked by Wall St. Rank hold ARRY as of Q3 2018.

  • Piermont Capital Management reported no remaining Array Biopharma Inc position as of Q3 2018 after selling out during the quarter.
  • Piermont Capital Management sold 18,660 Array Biopharma Inc shares in Q3 2018, an estimated $313K.
  • Piermont Capital Management first reported a position in Array Biopharma Inc in Q1 2017 and held it in 6 quarters.
  • Piermont Capital Management's Array Biopharma Inc position peaked at $562K in Q1 2017.
  • 208 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2018.

Based on Piermont Capital Management's 13F filing for Q3 2018, filed 6 Nov 2018.